Medications & Treatments

Lantus competitor Basaglar wins FDA approval

Lantus competitor Basaglar wins FDA approval The Food and Drug Administration on Dec. 16 approved Lilly’s Basaglar (insulin glargine injection 100 unit/mL), a long-acting human…

Trulicity Trial Shows Benefits for Type 2 Diabetes

A yearlong clinical trial in more than a dozen countries reveals that once-a-week-Trulicity, used in conjunction with short acting insulin, not only improved blood sugar control for subjects with type 2 diabetes, but also curbed hypoglycemia compared t...